Central pancreatectomy - an oncologically safe option to treat metastases of other neoplasms of the mid-portion of the pancreas?

Traian Dumitrascu, Andra Scarlat, Miheea Ionescu, and Irinel Popescu

Center of General Surgery and Liver Transplant, Fundeni Clinical Institute, Bucharest, Romania

Backgrounds/Aims: Standard pancreatic resections are the current approach for patients with resectable, isolated pancreatic metastases of other neoplasms. However, the role of parenchyma-sparing pancreatectomies for such pathology is poorly investigated. The aim of the present study is to assess the oncological safety of central pancreatectomies for pancreatic metastases of other neoplasms. Methods: A literature search was performed in order to identify patients with central pancreatectomies for pancreatic metastases of other neoplasms. The available data of the patients were extracted and analyzed. Results: A total number of 16 patients were identified. Renal carcinoma was the primary origin for the largest number of these patients (11 patients - 69%). The mean overall survival time was 109 months, with 1-, 5- and 10-year survival rates of 100%, 84%, and 60%, respectively. Conclusions: Although not often performed, a central pancreatectomy appears to be an oncologically safe surgical procedure in select patients with pancreatic metastases of other neoplasms of the pancreatic body and isthmus. However, no definitive conclusions should be drawn, based on the data provided in the present study, due to the limited number and heterogeneity of the patients. (Ann Hepatobiliary Pancreat Surg 2017;21:76-79)

Key Words: Central pancreatectomy; Pancreatic metastases; Survival

INTRODUCTION

A central pancreatectomy is a conservative surgical procedure that preserves the spleen and pancreatic parenchyma. It was proposed as alternative to distal/extended distal pancreatectomies. The advantage of a central pancreatectomy is better preservation of both endocrine and exocrine pancreatic function, compared with a distal pancreatectomy, an extended distal pancreatectomy, and a spleen-preserving distal pancreatectomy. The major drawbacks of a central pancreatectomy are high morbidity and non-nil mortality rates, particularly in aged and obese patients with diabetes. Pancreatic fistulae represent the main source of morbidity after a central pancreatectomy, being reported in up to 63% of the patients. The majority of the reported central pancreatectomies worldwide were performed for a benign/low-grade malignant tumor of the mid-portion of the pancreas. Thus, cystadenomas and pancreatic neuroendocrine tumors were the main indications for a central pancreatectomy. However, the role of a central pancreatectomy for pancreatic malignancies, such as pancreatic metastases of other neoplasms, is poorly investigated.

The aim of the present study is to assess the oncological safety of central pancreatectomies for pancreatic metastases of other neoplasms, based on data reported in the literature.

MATERIALS AND METHODS

Patients

Patients were extracted from articles identified by electronic searching in PubMed-Medline and Google Scholar and by reviewing the references of the identified articles. The searched words were “central pancreatectomy”, “medial pancreatectomy”, “median pancreatectomy”, “meso-pancreatectomy”, “middle pancreatectomy”, “segmental resection of the pancreas”, “middle segmental resection of the
Table 1. The long-term outcomes of the patients with a central pancreatectomy for pancreatic metastases of other neoplasms reported in the literature

| Reference          | Primary neoplasm          | Long-term outcomes                                                                 |
|--------------------|---------------------------|-----------------------------------------------------------------------------------|
| de Clavière, 2002  | Renal carcinoma           | Pancreatic, liver and lung recurrence at 58 months; DOD at 75 months               |
| Sauvanet, 2002     | Renal carcinoma           | Alive with pancreatic recurrence at 60 months                                     |
| Müller, 2006       | Renal carcinoma           | Alive with no recurrence at 33 months                                             |
|                    | Renal carcinoma           | Postoperative death due to hemorrhage (day 10)                                    |
| Crippa, 2007       | Renal carcinoma           | Alive with no recurrence at 137 months                                            |
|                    | Melanoma                  | Alive with no recurrence at 30 months                                            |
| Dumitraşcu, 2008   | Melanoma                  | Pancreatic and peritoneal recurrence at 30 months; DOD at 46 months               |
|                    | Renal carcinoma           | Alive with no recurrence at 12 months                                            |
| Hirono, 2009       | Renal carcinoma           | Alive with no recurrence at 12 months                                            |
| Deguchi, 2009      | Renal carcinoma           | Alive with no recurrence at 12 months                                            |
| Cataldeğirmen, 2010| Renal carcinoma           | Alive with no recurrence at 12 months                                            |
|                    | Breast carcinoma          | Alive with no recurrence at 12 months                                            |
| Shikano, 2010      | Hemangiopericytoma        | Alive with no recurrence at 12 months                                            |
| Goudard, 2014      | Renal carcinoma           | Pancreatic recurrence at 58 months - distal spleno-pancreatectomy; alive with no recurrence at 92 months |
|                    | Renal carcinoma           | Pancreatic recurrence at 59 months - distal spleno-pancreatectomy; alive without recurrence at 88 months |
| Dumitraşcu, 2015   | Colon carcinoma           | Peritoneal recurrence at 18 months; DOD at 28 months                              |

DOD, died of the disease; NA, not available

Statistical analysis

Statistical analysis was performed with SPSS (Statistical Packages for Social Sciences; SPSS Inc.; Chicago, IL, USA), version 17.0 software. The mean overall survival time was estimated using the Kaplan-Meier curve.

RESULTS

A total number of 16 patients with central pancreatectomies for pancreatic metastases of other neoplasms were identified worldwide, as shown in Table 1. Renal carcinoma was the primary origin for the largest number of patients (11 patients - 69%). The mean overall survival time of the patients was 109 months, with 1-, 5- and 10-year survival rates of 100%, 84%, and 60%, respectively (Fig. 1).

DISCUSSION

Isolated pancreatic metastases of other neoplasms represent an uncommon pathology and accounts for 2%-5% of all pancreatic malignancies. Thus, the reported series includes a relatively small number of patients, with most of the patients having had a renal carcinoma as the primary tumor, as was the case in the present cohort of patients. Furthermore, pancreatic metastases of other neoplasms represent only 0.01%-1.8% of the indications for pancreatic resections.

Given the rarity of such pathology, an evidence-based
surgical approach is not available. Standard pancreatic resections (i.e., pancreaticoduodenectomy, distal spleno-pancreatectomy, total pancreatectomy) are the common approaches for patients with a resectable disease. However, it is not clear if pancreatic metastases of other neoplasms should share the same oncological principles as ductal adenocarcinoma of the pancreas. Negative resection margins can be achieved in some patients with central pancreatectomies for pancreatic metastases of other neoplasms but a standard lymph node dissection cannot be accomplished with this conservative surgical procedure.

The role of a systematic, loco-regional lymph node dissection for pancreatic metastases of other neoplasms remains controversial. Some studies did not find any survival differences between the standard pancreatic resections and atypical pancreatectomies for pancreatic metastases of other neoplasms and, thus, these studies do not support the routine use of systematic, loco-regional lymph node dissection. However, there is a study showing that atypical pancreatic resections are associated with high recurrence rates. Nevertheless, there are also studies that identified metastatic lymph nodes in patients with standard pancreatectomies for isolated pancreatic metastases of other neoplasms in up to 35% of the cases.

After standard pancreatic resections for isolated pancreatic metastases of other neoplasms the reported median/mean survival time varied between 19 to 119 months, with 5-year survival rates between 36.2% and 88%. These results are comparable with those reported in the present study. Consequently, a central pancreatectomy appears to have similar oncological outcomes to standard pancreatic resections.

Pancreatic metastases of other neoplasms are widely considered to be a part of a systemic oncological disease. These patients are likely to receive chemotherapy. Chemotherapy in a patient with diabetes can be challenging because some chemotherapeutic agents can lead to or exacerbate potential renal, cardiac or neuropathic complications. Thus, sparing the pancreatic parenchyma represents an important issue because they are likely to receive chemotherapy. A conservative pancreatectomy has the potential to mitigate the complications of chemotherapy by reducing the risk of postoperative diabetes, which is the lowest after a central pancreatectomy, compared with standard pancreatic resections. However, no definitive conclusions should be drawn based on the data provided in the present study due to the limited number and heterogeneity of the patients.

ACKNOWLEDGEMENTS

An early version of the manuscript was presented at the 44th Congress of the Korean Association of HBP Surgery (April 1-2, 2016, Seoul, Korea). Traian Dumitrascu received a travel grant from the Korean Association of HBP Surgery.

REFERENCES

1. Dumitrascu T, Popescu I. Central pancreatectomy revisited. J Transl Med Res 2015;20:185-194.
2. Iacono C, Verlato G, Ruzzenente A, Campagnaro T, Baccelli C, Valdegamberi A, et al. Systematic review of central pancreatectomy and meta-analysis of central versus distal
pancreatectomy. Br J Surg 2013;100:873-885.

3. Cataldeğirmen G, Schneider CG, Bogoevski D, Koenig A, Kaifi JT, Bochkorn M, et al. Extended central pancreatic resection as an alternative for extended left or extended right resection for appropriate pancreatic neoplasms. Surgery 2010;147:331-338.

4. Dumitrascu T, Scarlat A, Ionescu M, Popescu I. Central pancreatectomy versus spleen-preserving distal pancreatectomy: a comparative analysis of early and late operative outcomes. Dig Surg 2012;29:400-407.

5. Dumitrascu T, Barbu ST, Ionescu M, Popescu I. POSSUM, a potentially useful tool for prediction of morbidity in patients undergoing central pancreatectomy. Chirurgia (Bucur) 2012;107:447-453.

6. Goudard Y, Gaujoux S, Dokmak S, Cros J, Couvelard A, Palazzo M, et al. Reappraisal of central pancreatectomy a 12-year single-center experience. JAMA Surg 2014;149:356-363.

7. Dumitrascu T, Barbu ST, Purnichescu-Purtan R, Ionescu M, Popescu I. Risk factors for surgical complications after central pancreatectomy. Hepatogastroenterology 2012;59:592-598.

8. Crippa S, Bassi C, Warshaw AL, Falconi M, Partelli S, Thayer SP, et al. Middle pancreatectomy: indications, short- and long-term operative outcomes. Ann Surg 2007;246:69-76.

9. de Clavière G, Paye F, Fteriche S, Terris B, Belghiti J, Sauvanet A. Medial pancreatectomy: results of a series of 11 patients. Ann Chir 2002;127:48-54.

10. Deguchi Y, Shimada K, Sara N, Esaki M, Sakamoto Y, Kosuge T, et al. Pancreatecticojejunostomy with invasioning of the punched pancreatic remnant after medial pancreatectomy and enucleation for multiple metastases of renal cell carcinoma: report of a case. Surg Today 2009;39:1086-1090.

11. Dumitrascu T, Scarlat A, Ciurea S, Popescu I. Central pancreatectomy for a pancreatic metastasis of colon cancer - a case report. J Transl Med Res 2015;20:153-156.

12. Dumitrascu T, Dima S, Popescu C, Gheonea DI, Ciurea T, Salfouiu A, et al. An unusual indication for central pancreatectomy–late pancreatic metastasis of ocular malignant melanoma. Chirurgia (Bucur) 2008;103:479-485.

13. Hirono S, Tani M, Kawai M, Ina S, Nishioka R, Miyazawa M, et al. A central pancreatectomy for benign or low-grade malignant neoplasms. J Gastrointest Surg 2009;13:1659-1665.

14. Müller MW, Friess H, Kleeff J, Hinz U, Wente MN, Paranythiosis D, et al. Middle segmental pancreatic resection: An option to treat benign pancreatic body lesions. Ann Surg 2006;244:909-918.

15. Sauvanet A, Partensky C, Sastre B, Gigot JF, Fagniez PL, Tuech JJ, et al. Medial pancreatectomy: a multi-institutional retrospective study of 53 patients by the French Pancreas Club. Surgery 2002;132:836-843.

16. Shikano T, Nakao A, Kodera Y, Yamada S, Fuji T, Sugimoto H, et al. Middle pancreatectomy: safety and long-term results. Surgery 2010;147:21-29.

17. Adler H, Redmond CE, Heneghan HM, Swan N, Maguire D, Traynor O, et al. Pancreatectomy for metastatic disease: a systematic review. Eur J Surg Oncol 2014;40:379-386.

18. Reddy S, Wolfgang CL. The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol 2009;10:287-293.

19. Crippa S, Angelini C, Mussi C, Bonardi C, Romano F, Sartori P, et al. Surgical treatment of metastatic tumors to the pancreas: a single center experience and review of the literature. World J Surg 2006;30:1536-1542.

20. Strobel O, Hackert T, Hartwig W, Bergmann F, Hin z U, Wente MN, et al. Survival data justifies resection for pancreatic metastases. Ann Surg Oncol 2009;16:3340-3349.

21. Untch BR, Allen PJ. Pancreatectectomy: the Memorial Sloan-Kettering experience and a review of the literature. J Surg Oncol 2014;109:28-30.

22. Konstantinidis IT, Dursun A, Zheng H, Wargo JA, Thayer SP, Fernandez-del Castillo C, et al. Metastatic tumors in the pancreas in the modern era. J Am Coll Surg 2010;211:749-753.

23. Kwak JH, Heo JS, Park JY, Choi DW, Choi SH, Lee HS. Outcomes of pancreaticoduodenectomy in patients with metastatic cancer. Korean J Hepatobiliary Pancreat Surg 2014;18:147-151.

24. Yazbek T, Gayet B. The place of enucleation and enucleo-resection in the treatment of pancreatic metastasis of renal cell carcinoma. JOP 2012;13:433-438.

25. Cerbi A, Ortolano E, Balzano G, Borri A, Beneduce AA, Di Carlo V. Pancreatectectomy from renal cell carcinoma: which patients benefit from surgical resection? Ann Surg Oncol 2008;15:1161-1168.

26. Bassi C, Butturini G, Falconi M, Sargenti M, Mantovani W, Pederzoli P. High recurrence rate after atypical resection for pancreatic metastases from renal cell carcinoma. Br J Surg 2003;90:555-559.

27. Reddy S, Edil BH, Cameron JL, Pawlik TM, Herman JM, Gilson MM, et al. Pancreatectomy of isolated metastases from non-pancreatic primary cancers. Ann Surg Oncol 2008;15:3199-3206.

28. Psarakis HM. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectr 2006;19:157-162.

29. Jeong Y, Han HS, Lee HD, Yang J, Jeong J, Choi MK, et al. A Pilot Study evaluating steroid-induced diabetes after antie-metic dexamethasone therapy in chemotherapy-treated cancer patients. Cancer Res Treat 2016;48:1429-1437.

30. Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, et al. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol 2015;22:2094-2100.